Q3 EPS Forecast for Adherex Technologies Reduced by Analyst

Key Points

• HC Wainwright has lowered its Q3 2025 earnings estimate for Adherex Technologies to ($0.09) per share, down from the previous estimate of ($0.04).
• Despite the pessimistic outlook, HC Wainwright maintains a "Buy" rating with a target price of $13.00, while other analysts have varied ratings ranging from "Strong Buy" to "Hold."
• Adherex Technologies missed its recent earnings estimate, reporting ($0.11) EPS for the quarter, compared to the consensus estimate of ($0.06).

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Adherex Technologies in a research note issued to investors on Thursday, August 21st. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.09) for the quarter, down from their prior estimate of ($0.04). HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Adherex Technologies' current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies' FY2025 earnings at ($0.25) EPS and FY2026 earnings at $0.65 EPS.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The business had revenue of $9.76 million during the quarter, compared to analysts' expectations of $9.52 million.

Other research analysts have also issued reports about the company. Zacks Research lowered Adherex Technologies from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. Craig Hallum raised their price target on Adherex Technologies from $13.00 to $14.00 and gave the stock a "buy" rating in a research report on Friday, August 15th. Finally, Wall Street Zen upgraded Adherex Technologies from a "hold" rating to a "buy" rating in a research report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $13.33.

Adherex Technologies Price Performance

FENC remained flat at $8.87 during mid-day trading on Monday. The company's stock had a trading volume of 31,949 shares, compared to its average volume of 68,267. The company has a market cap of $246.67 million, a PE ratio of -21.12 and a beta of 0.40. The stock has a 50 day moving average price of $8.52 and a two-hundred day moving average price of $7.28. Adherex Technologies has a 52-week low of $3.96 and a 52-week high of $9.42.

Insider Buying and Selling

In other Adherex Technologies news, Director Rosty Raykov sold 10,000 shares of Adherex Technologies stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $8.09, for a total value of $80,900.00. Following the sale, the director owned 55,878 shares of the company's stock, valued at $452,053.02. This trade represents a 15.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 31,119 shares of company stock worth $254,546. Company insiders own 11.76% of the company's stock.

Institutional Trading of Adherex Technologies

Several hedge funds and other institutional investors have recently modified their holdings of FENC. Geode Capital Management LLC raised its stake in shares of Adherex Technologies by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 303,090 shares of the company's stock valued at $1,916,000 after purchasing an additional 3,792 shares during the period. Wells Fargo & Company MN raised its stake in shares of Adherex Technologies by 31.6% in the 4th quarter. Wells Fargo & Company MN now owns 13,152 shares of the company's stock valued at $83,000 after purchasing an additional 3,155 shares during the period. Barclays PLC raised its stake in shares of Adherex Technologies by 13.9% in the 4th quarter. Barclays PLC now owns 35,672 shares of the company's stock valued at $225,000 after purchasing an additional 4,353 shares during the period. MetLife Investment Management LLC acquired a new stake in shares of Adherex Technologies in the 4th quarter valued at about $99,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Adherex Technologies by 11.5% in the 4th quarter. BNP Paribas Financial Markets now owns 44,626 shares of the company's stock valued at $282,000 after purchasing an additional 4,610 shares during the period. Institutional investors and hedge funds own 55.51% of the company's stock.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.